Altered vascular reactivity and KATP channel currents in vascular smooth muscle cells from deoxycorticosterone acetate (DOCA)-salt hypertensive rats.
This study was designed to evaluate the contribution of ATP-dependent potassium (KATP) channels to the changes in vascular reactivity and spontaneous tone observed in vessels isolated from deoxycorticosterone acetate (DOCA)-salt hypertensive rats. In phenylephrine preconstricted aortic rings, cromakalim induced concentration-dependent, glibenclamide-sensitive relaxation. The concentration response curve to cromakalim was shifted to the right in DOCA-salt hypertensive rats (EC50: 0.850 +/- 0.100 microM) compared with SHAM-normotensive rats (0.108 +/- 0.005 microM), and the maximum relaxation (Emax) evoked by cromakalim was significantly lower in aortic rings from the DOCA group (68 +/- 2%) compared with the SHAM group (108 +/- 5%). The results were similar in endothelium-denuded rings. Spontaneous tone was observed in aortic rings (5 g preload) from DOCA-salt but not SHAM rats. Cromakalim abolished spontaneous tone and the effect was blocked by glibencamide. In whole cell patch clamp studies, increasing extracellular K concentrations from 5.4 to 140 mM and the administration of cromakalim evoked dramatic increases in KATP channel currents in aortic cells isolated from SHAM rats. In contrast, in aortic cells from DOCA-salt hypertensive rats, KATP channel currents were either absent or weak in response to challenges by elevated extracellular K and by cromakalim. These findings suggest that the function of KATP channels is impaired in smooth muscle cells from aorta of DOCA-salt hypertensive rats, which may contribute to the impaired vasodilatation and spontaneous tone observed in these rats.
Ghosh
Mahua
M
Department of Pharmacology, University of Saskatchewan, Saskatoon, Canada.
Hanna
Salma T
ST
Wang
Rui
R
McNeill
J Robert
JR
D000255:Adenosine Triphosphate / Q000494:pharmacology / Q000502:physiology*; D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects / Q000293:injuries / Q000473:pathology; D001794:Blood Pressure / Q000187:drug effects; D002170:Canada; D019806:Cromakalim / Q000037:antagonists & inhibitors / Q000494:pharmacology; D003900:Desoxycorticosterone; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004343:Drug Implants / Q000008:administration & dosage; D004594:Electrophysiology / Q000379:methods; D004730:Endothelium, Vascular / Q000187:drug effects / Q000293:injuries / Q000473:pathology; D005905:Glyburide / Q000494:pharmacology; D006973:Hypertension / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology*; D009392:Nephrectomy / Q000379:methods; D010656:Phenylephrine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D015221:Potassium Channels / Q000145:classification / Q000187:drug effects / Q000502:physiology*; D011189:Potassium Chloride / Q000378:metabolism / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D014661:Vasoconstriction / Q000187:drug effects / Q000502:physiology; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology
D004343:Drug Implants; D015221:Potassium Channels; D019806:Cromakalim; D010656:Phenylephrine; D003900:Desoxycorticosterone; D011189:Potassium Chloride; D000255:Adenosine Triphosphate; D005905:Glyburide